Requirement of diverse T-helper responses elicited by HIV vaccines: Induction of highly targeted humoral and CTL responses

Expert Review of Vaccines

Volumn 3, Issue 4 SUPPL., 2004, Pages

  Heeney, Jonathan Luke ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

Adjuvants; CD4; Conserved epitopes; CTL; Cytokines; HIV vaccine; IL 2; Mimotopes; Neutralizing antibodies; Review; T helper; Vaccine efficacy

Indexed keywords

CD4 ANTIGEN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOPROPHYLAXIS; MUCOSAL IMMUNITY; NONHUMAN; POLITICS; PRIMATE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SOCIAL ASPECT; VIROLOGY; VIRUS ENVELOPE;

AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 4344649886     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.4.S53     Document Type: Review

References (83)

1. McDermott AB, Mitchen J, Piaskowski S et al. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J. Virol. 78, 3140-3144 (2004).
2. Miller CJ, Marthas M, Greenier J, Lu D, Dailey PJ, Lu Y. In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques. J. Virol 72, 3248-3258 (1998).
3. + T-cells. Science 286, 1353-1357 (1999).
4. Copeland KF, Heeney JL. T-helper cell activation and human retroviral pathogenesis. Microbiol. Rev. 60, 722-742 (1996).
5. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nature Rev. Immunol. 2, 569-579 (2002).
6. Wei X, Decker JM, Wang S et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
7. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV Type 1 infection. Proc. Natl Acad. Sci. USA 100, 4144-4149 (2003).
8. Burton DR, Desrosiers RC, Doms RW et al. HIV vaccine design, and the neutralizing antibody problem. Nature Immunol. 5, 233-236 (2004).
9. Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus bypassive infusion of neutralizing antibodies. Nature Med. 6, 207-210 (2000).
10. Baba TW, Liska V, Hofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nature Med. 6, 200-206 (2000).
11. Igarashi T, Brown C, Azadegan A et al. Human immunodeficiency virus Type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nature Med. 5, 211-216 (1999).
12. Chien PC Jr., Cohen S, Tuen M et al. Human immunodeficiency virus Type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing. J. Virol. 78, 7645-7652 (2004).
13. Saphire EO, Parren PW, Pantophlet R et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293, 1155-1159 (2001).
14. Trkola A, Purtscher M, Master T et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus Type 1. J. Virol. 70, 1100-1108 (1996).
15. Barnett SW, Lu S, Srivastava I et al. The ability of an oligomeric human immunodeficiency virus Type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75, 5526-5540 (2001).
16. Huang Y, Kong WP, Nabel GJ. Human immunodeficiency virus Type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol. 75, 4947-4951 (2001).
17. Chakrabarti BK, Kong WP, Wu BY et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol. 76, 5357-5368 (2002).
18. Berman PW, Gregory TJ, Riddle L et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345, 622-625 (1990).
19. Girard M, Kieny MP, Pinter A et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl Acad. Sci. USA 88, 542-546 (1991).
20. Bruck C, Thiriart C, Fabry L et al. HIV-1 envelope-elicited neutralizing antibody titers correlate with protection and virus load in chimpanzees. Vaccine 12, 1141-1148 (1994).
21. ten Haaft P, Cornelissen M, Goudsmit J et al. Virus load in chimpanzees infected with human immunodeficiency virus Type 1, effect of pre-exposure vaccination. J. Gen. Virol. 76(Pt 4), 1015-1020 (1995).
22. Berman PW, Murthy KK, Wrin T et al. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus Type 1. J. Infect. Dis. 173, 52-59 (1996).
23. Girard M, Yue L, Barre-Sinoussi F et al. Failure of a human immunodeficiency virus Type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain. J. Virol. 70, 8229-8233 (1996).
24. Emini EA, Schleif WA, Nunberg JH et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728-730 (1992).
25. Conley AJ, Kessler JA, II, Boots LJ et al. The consequence of passive administration of an antihuman immunodeficiency virus Type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70, 6751-6758 (1996).
26. Putkonen P, Thorstensson R, Ghavamzadeh L et al. Prevention of HIV-2 and SIVsm infection bypassive immunization in cynomolgus monkeys. Nature 352, 436-438 (1991).
27. Shibata R, Igarashi T, Haigwood N et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Med. 5, 204-210 (1999).
28. Gorny MK, Xu JY, Gianakakos VA et al. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus Type 1 envelope glycoprotein. Proc. Natl Acad. Sci. USA 88, 3238-3242 (1991).
29. Gorny MK, Xu JY, Karwowska S, Buchbinder A, Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150, 635-643 (1993).
30. Gorny MK, Conley AJ, Karwowska S et al. Neutralization of diverse human immunodeficiency virus Type 1 variants by an antiV3 human monoclonal antibody. J Virol. 66, 7538-7542 (1992).
31. Hioe CE, Xu S, Chigurupati P et al. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int. Immunol. 9, 1281-1290 (1997).
32. Sharon M, Kessler N, Levy R, Zolla-Pazner S, Gorlach M, Anglister J. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (Camb) 11, 225-236 (2003).
33. Moore JP, Trkola A, Korber B et al. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus Type 1 has broad reactivity within and outside clade B. J. Virol. 69, 122-130 (1995).
34. Burton DR, Barbas CF, 3rd, Persson MA, Koenig S, Chanock RM, Lerner RA. A large array of human monoclonal antibodies to Type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl Acad. Sci. USA 88, 10134-10137 (1991).
35. Burton DR, Pyati J, Koduri R et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027 (1994).
36. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus Type 1. J. Virol. 68, 4821-4828 (1994).
37. Trkola A, Pomales AB, Yuan H et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus Type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69, 6609-6617 (1995).
38. Kessler JA, 2nd, McKenna PM, Emini EA et al. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus Type 1 primary isolates. AIDS Res. Hum. Retroviruses 13, 575-582 (1997).
39. Zwick MB, Parren PW, Saphire EO et al. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus Type 1 gp120. J. Virol 77, 5863-5876 (2003).
40. Scanlan CN, Pantophlet R, Wormald MR et al. The broadly neutralizing antihuman immunodeficiency virus Type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J. Virol. 76, 7306-7321 (2002).
41. Sanders RW, Venturi M, Schiffner L et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus Type 1 glycoprotein gp120. J. Virol. 76, 7293-7305 (2002).
42. Moore JP, Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus Type 1 gp120 exterior envelope glycoprotein. J. Virol. 70, 1863-1872 (1996).
43. Poignard P, Sabbe R, Picchio GR et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10, 431-438 (1999).
44. Calarese DA, Scanlan CN, Zwick MB et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065-2071 (2003).
45. Zwick MB, Labrijn AF, Wang M et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus Type 1 glycoprotein gp41. J. Virol. 75, 10892-10905 (2001).
46. Stiegler G, Kunert R, Purtscher M et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus Type 1. AIDS Res. Hum. Retroviruses 17, 1757-1765 (2001).
47. Muster T, Steindl F, Purtscher M et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus Type 1. J. Virol. 67, 6642-6647 (1993).
48. Zwick MB, Komori HK, Stanfield RL et al. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing antihuman immunodeficiency virus Type 1 antibody 2F5. J. Virol. 78, 3155-3161 (2004).
49. Parker CE, Deterding LJ, Hager-Braun C et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus Type 1 for the neutralizing monoclonal antibody 2F5. J. Virol. 75, 10906-10911 (2001).
50. Joyce JG, Hurni WM, Bogusky MJ et al. Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J. Biol. Chem. 277, 45811-45820 (2002).
51. Moulard M, Phogat SK, Shu Y et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl Acad. Sci. USA 99, 6913-6918 (2002).
52. Heeney JL, van Els C, de Vries P et al. Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. J. Exp. Med. 180, 769-774 (1994).
53. Gallimore A, Cranage M, Cook N et al. Early suppression of SIV replication by CDS+ nef-specific cytotoxic T-cells in vaccinated macaques. Nature Med. 1, 1167-1173 (1995).
54. Shiver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
55. Barouch DH, Kunstman J, Kuroda MJ et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T-lymphocytes. Nature 415, 335-339 (2002).
56. + lymphocytes. Science 283, 857-860 (1999).
57. Jin X, Bauer DE, Tuttleton SE et al. Dramatic rise in plasma viremia after CD8(+) T-cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991-998 (1999).
58. Kaslow RA, Carrington M, Apple R et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med. 2, 405-411 (1996).
59. Leslie AJ, Pfafferott KJ, Chetty P et al. HIV evolution: CTL escape mutation and reversion after transmission. Nature Med. 10, 282-289 (2004).
60. Evans DT, O'Connor DH, Jing P et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nature Med. 5, 1270-1276 (1999).
61. Barouch DH, Craiu A, Kuroda MJ et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl Acad. Sci. USA 97, 4192-4197 (2000).
62. Mooij P, Heeney JL. Rational development of prophylactic HIV vaccines based on structural and regulatory proteins. Vaccine 20, 304-321 (2001).
63. Heeney JL. AIDS: a disease of impaired Th-cell renewal? Immunol. Today 16, 515-520 (1995).
64. Balla-Jhagjhoorsingh SS, Verschoor EJ, de Groot N, Teeuwsen VJ, Bontrop RE, Heeney JL. Specific nature of cellular immune responses elicited by chimpanzees against HIV-1. Hum. Immunol. 64, 681-688 (2003).
65. +CD45RA-CD62L-CCR7-memory T-helper cells. AIDS 18, 837-848 (2004).
66. Balla-Jhagjhoorsingh SS, Koopman G, Mooij P et al. Conserved CTL epitopes shared between HIV-infected human long-term survivors and chimpanzees. J. Immunol. 162, 2308-2314 (1999).
67. Hamann D, Baars PA, Rep MH et al. Phenotypic and functional separation of memory and effector human CD8+ T-cells. J. Exp. Med. 186, 1407-1418 (1997).
68. Champagne P, Ogg GS, King AS et al. Skewed maturation of memory HIV-specific CD8 T-lymphocytes. Nature 410, 106-111 (2001).
69. Gougeon ML, Lecoeur H, Boudet F et al. Lack of chronic immune activation in HIV-infected chimpanzees correlates with the resistance of T-cells to Fas/Apo-1 (CD95)-induced apoptosis and preservation of a T-helper 1 phenotype. J. Immunol. 158, 2964-2976 (1997).
70. Koopman G, Niphuis H, Newman W, Kishimoto TK, Maino VC, Heeney JL. Decreased expression of IL-2 in central and effector CD4 memory cells during progression to AIDS in rhesus macaques. AIDS 15, 2359-2369 (2001).
71. Heeney J. ten Haaft P, Dubbes R et al. Protection from HIV-1 infection and virus load is related to pre-challenge neutralization titers in HIV-1 vaccinated chimpanzees. Vaccines 94, CSH Laboratory Press 269-278 (1994).
72. van der Meide PH, Groenestein RJ, de Labie MC, Heeney J, Pala P, Slaoui M. Enumeration of lymphokine-secreting cells as a quantitative measure for cellular immune responses in rhesus macaques. J. Med. Primatol. 24, 271-281 (1995).
73. Heeney JL, Teeuwsen VJ, van Gils M et al. beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc. Natl Acad Sci. USA 95, 10803-10808 (1998).
74. Verschoor EJ, Mooij P, Oostermeijer H et al. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus Type 1 vaccines in Rhesus macaques: evidence for viral clearance. J. Virol. 73, 3292-3300 (1999).
75. Heeney J, Akerblom L, Barnett S et al. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunol. Lett. 66, 189-195 (1999).
76. + T-cell memory. Science 297, 2060-2063 (2002).
77. + T-lymphocytes. Nature 421, 852-856 (2003).
78. Kaech SM, Ahmed R. Immunology. CD8 T-cells remember with a little help. Science 300, 263-265 (2003).
79. Shedlock DJ, Shen H. Requirement for CD4 T-cell help in generating functional CDS T-cell memory. Science 300, 337-339 (2003).
80. Sun JC, Bevan MJ. Defective CD8 T-cell memory following acute infection without CD4 T-cell help. Science 300, 339-342 (2003).
81. Mooij P, Nieuwenhuis IG, Knoop CJ et al. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J. Virol. 78, 3333-3342 (2004).
82. Brenchley JM, Hill BJ, Ambrozak DR et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J. Virol. 78, 1160-1168 (2004).
83. + T-cells. Nature 417, 95-98 (2002).